A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells*
暂无分享,去创建一个
A. Levine | A. Chicas | J. Bargonetti | G. Bond | N. Arva | L. Campbell | Kathryn E. Talbott | David E. White | T. Gopen
[1] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[2] M. Oren,et al. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. , 2004, Molecular cell.
[3] Xinbin Chen,et al. MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53* , 2004, Journal of Biological Chemistry.
[4] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[5] P. Chène,et al. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.
[6] D. Livingston,et al. Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.
[7] J. Bargonetti,et al. In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability. , 2003, Methods in molecular biology.
[8] M. Olivier,et al. Differential Activation of p53 by the Various Adducts of Mitomycin C* , 2002, The Journal of Biological Chemistry.
[9] J. Borowiec,et al. Stress-Dependent Nucleolin Mobilization Mediated by p53-Nucleolin Complex Formation , 2002, Molecular and Cellular Biology.
[10] L. Freedman,et al. Reciprocal Recruitment of DRIP/Mediator and p160 Coactivator Complexes in Vivo by Estrogen Receptor* , 2002, The Journal of Biological Chemistry.
[11] J. Manfredi,et al. Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.
[12] Shengyun Fang,et al. Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.
[13] D. Meek,et al. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2 , 1999, The EMBO journal.
[14] A. Levine,et al. Functions of the MDM2 oncoprotein , 1999, Cellular and Molecular Life Sciences CMLS.
[15] J. Niland,et al. The MDM2 gene amplification database. , 1998, Nucleic acids research.
[16] J. Bargonetti,et al. p53 binds to a constitutively nucleosome free region of the mdm2 gene , 1998, Oncogene.
[17] N. Tuteja,et al. Nucleolin: a multifunctional major nucleolar phosphoprotein. , 1998, Critical reviews in biochemistry and molecular biology.
[18] R. Tjian,et al. Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.
[19] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[20] Xiao-Fan Wang,et al. Functional Analysis of the Transforming Growth Factor βResponsive Elements in the WAF1/Cip1/p21 Promoter (*) , 1995, The Journal of Biological Chemistry.
[21] K. Kinzler,et al. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.
[22] J. Landers,et al. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. , 1994, Oncogene.
[23] X. Chen,et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.
[24] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[25] A. Levine,et al. Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.
[26] M. Oren,et al. Sequence‐specific DNA binding by p53: identification of target sites and lack of binding to p53 ‐ MDM2 complexes. , 1993, The EMBO journal.
[27] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[28] D. Lane,et al. Regulation of the specific DNA binding function of p53 , 1992, Cell.
[29] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[30] B. Vogelstein,et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.
[31] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[32] D. Ledbetter,et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.